期刊
JOURNAL OF CLINICAL MEDICINE
卷 11, 期 21, 页码 -出版社
MDPI
DOI: 10.3390/jcm11216369
关键词
direct oral anticoagulants; tailored medicine; DOAC laboratory monitoring; atrial fibrillation; adverse thrombotic and hemorrhagic events
资金
- project APVV (Slovak Research and Development Agency) [16-0020]
- Projects of Research Agency of Slovak Ministry of Education, Science and Sports (VEGA) [1/0549/19, 1/0090/20]
DOAC is currently the drug of choice for preventing stroke or systemic embolism in AF patients, but there is still a challenge in optimizing its clinical efficacy.
Direct oral anticoagulants (DOAC) are currently the drug of choice for drug prevention of stroke or systemic embolism in patients with atrial fibrillation (AF). However, repeated ischemic stroke or systemic embolism and bleeding while on DOAC is still a challenging clinical phenomenon in the management of future long-term anticoagulation. It is not known whether tailoring the DOAC therapy to achieve optimal therapeutic drug levels could improve the clinical course of DOAC therapy. To be able to tailor the therapy, it is necessary to have a valid laboratory method for DOAC level assessment, to be aware of factors influencing DOAC levels and to have clinical options to tailor the treatment. Furthermore, the data regarding clinical efficacy/safety of tailored DOAC regimes are still lacking. This article reviews the current data on tailored direct oral anticoagulation in patients with AF.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据